Skip to content
2000
image of A Comprehensive Review of Designing and Synthetic Aspects of Pyrazolopyrimidine Derivatives as Anticancer Agents

Abstract

Background

Pyrazolopyrimidines are a fascinating class of heterocyclic compounds that have attracted considerable interest for their potential in cancer therapy. Their unique scaffold allows flexible chemical modifications, enabling them to interact with various cancer-related proteins—especially kinases that regulate tumor growth and survival.

Objective

This review highlights recent advancements in the design, synthesis, and biological evaluation of pyrazolopyrimidine derivatives, emphasizing their role as targeted anticancer agents.

Methods

We analyzed recent literature (2000–2025) covering synthetic strategies, anticancer targets, in silico studies on anticancer targets and their mechanisms, off-target mechanisms, and patent information. The review also focuses on how these methods guide the optimization of Structure–Activity Relationships (SAR) and improve compound efficacy.

Results

Numerous pyrazolopyrimidine derivatives demonstrated significant anticancer activity across various cell lines, including breast, liver, colorectal, and haematological malignancies. Mechanistic investigations revealed that these derivatives target key oncogenic pathways, such as CDKs, EGFR (including resistant mutants), mTOR, TOPO II, and HDACs. They exert anticancer effects by inducing apoptosis, arresting cells at S or M phases, and downregulating proliferation markers. Several studies also report favourable selectivity for cancer cells, improved bioavailability, and metabolic stability, supporting their drug-like properties.

Discussion

When rational drug-design approaches such as molecular docking, DFT calculations, and ADME profiling are considered together, pyrazolopyrimidine derivatives stand out as particularly promising multi-target anticancer agents. Across multiple studies, several compounds display anticancer activities that are comparable to, and occasionally stronger than, those of standard chemotherapeutic drugs like doxorubicin and cisplatin. Importantly, these effects are often accompanied by better selectivity toward cancer cells, suggesting a potential safety advantage. A noteworthy strength of this scaffold is its ability to target clinically relevant resistance pathways, including P-glycoprotein–mediated drug efflux and EGFR T790M mutations, which frequently limit the effectiveness of current therapies. While their ATP-mimetic binding mode allows interaction with a broad range of kinases, it also underscores the need for careful optimization to improve target selectivity and reduce unintended interactions. Although the available in vitro results and early in vivo studies indicate meaningful tumor growth inhibition with minimal toxicity, further work is clearly needed. Detailed pharmacokinetic, pharmacodynamic, and long-term toxicological studies will be essential before these compounds can be realistically advanced toward clinical application.

Conclusion

Pyrazolopyrimidines represent a versatile and promising class with efficacy, selectivity, and a favorable toxicity profile. Their ability to engage multiple targets and overcome resistance highlights their potential for integration in oncology. However, further systematic and clinical studies are essential to translate their potential into therapeutic success.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/mrmc/10.2174/0113895575417710251128043828
2026-01-07
2026-03-02

  • From This Site

    /content/journals/mrmc/10.2174/0113895575417710251128043828
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Allam H. Fahim S.H. Yahya T.A. Ragab F.A. Synthesis of Some Pyrazolo [1, 5-A] Pyrimidine Derivatives Bearing Carbonitrile, Amidoxime, Carboxamide And Oxadiazole Substituents Using Commercially Available Reagents. Egypt. J. Chem. 2024 67 3 475 482
    [Google Scholar]
  2. Nemr M.T.M. Elshewy A. Ibrahim M.L. El Kerdawy A.M. Halim P.A. Design, synthesis, antineoplastic activity of new pyrazolo[3,4-d]pyrimidine derivatives as dual CDK2/GSK3β kinase inhibitors; molecular docking study, and ADME prediction. Bioorg. Chem. 2024 150 107566 10.1016/j.bioorg.2024.107566 38896936
    [Google Scholar]
  3. Iorkula T.H. Jude-Kelly Osayawe O. Odogwu D.A. Ganiyu L.O. Faderin E. Awoyemi R.F. Akodu B.O. Ifijen I.H. Aworinde O.R. Agyemang P. Onyinyechi O.L. Advances in pyrazolo[1,5- a ]pyrimidines: synthesis and their role as protein kinase inhibitors in cancer treatment. RSC Advances 2025 15 5 3756 3828 10.1039/D4RA07556K 39911541
    [Google Scholar]
  4. Faris A. Cacciatore I. Alnajjar R. Aouidate A. AL Mughram M.H. Elhallaoui M. Computational insights into rational design and virtual screening of pyrazolopyrimidine derivatives targeting Janus kinase 3 (JAK3). Front Chem. 2024 12 1425220 10.3389/fchem.2024.1425220 39189018
    [Google Scholar]
  5. Al-Karmalawy A.A. Elmaaty A.A. Alabdali A.Y.M. Shaaban S. Khatib A.O.A. Abdellattif M.H. Alnjaa A.A. Sharaky M. Eldehna W.M. Gaber A.A. Exploring the anticancer potential of new pyrazolopyrimidine analogues as multi-target directed EGFR/STAT3 downregulatory candidates with apoptotic potential. New J. Chem. 2025 49 14 6025 6037 10.1039/D5NJ00367A
    [Google Scholar]
  6. Wal P. Wal A. Jawaid T. Ganguly P. Patel B. Nainwal P. Lari M.Q. Kumar A. Kumar D. Crossing Boundaries: A Review of the Diverse Functions of Heterocyclic Compounds in the Management of Cancer and Infectious Diseases. Curr. Drug Targets 2025 26 10.2174/0113894501372336250703114127 40641030
    [Google Scholar]
  7. Mahajan A.T. Shivani Datusalia A.K. Coluccini C. Coghi P. Chaudhary S. S. Pyrazolo [1, 5-a] pyrimidine as a prominent framework for tropomyosin receptor kinase (Trk) inhibitors—Synthetic strategies and SAR insights. Molecules 2024 29 15 3560 10.3390/molecules29153560 39124968
    [Google Scholar]
  8. Dorababu A. Role of heterocycles in inhibition of VEGFR-2 – a recent update (2019–2022). RSC Medicinal Chemistry 2024 15 2 416 432 10.1039/D3MD00506B 38389872
    [Google Scholar]
  9. Kumar H. Das R. Choithramani A. Gupta A. Khude D. Bothra G. Shard A. Efficient green protocols for the preparation of pyrazolopyrimidines. ChemistrySelect 2021 6 23 5807 5837 10.1002/slct.202101298
    [Google Scholar]
  10. Kassab A.E. Pyrazolo[3,4‐ d ]pyrimidine scaffold: A review on synthetic approaches and EGFR and VEGFR inhibitory activities. Arch. Pharm. (Weinheim) 2023 356 1 2200424 10.1002/ardp.202200424 36192144
    [Google Scholar]
  11. Lee H. Kim J. Kim J.W. Lee Y. Recent advances in AI-based toxicity prediction for drug discovery. Front Chem. 2025 13 1632046 10.3389/fchem.2025.1632046 40698059
    [Google Scholar]
  12. Rashid M. Kasana S. Nigam V. Islam M.M. Sanan R. Kurmi B.D. Asati V. Gupta G.D. Patel P. Ball-mill-assisted mechanochemical approaches for heterocyclic compound synthesis (2015–2024). Mol. Divers. 2025 1 38 10.1007/s11030‑025‑11176‑9 40208427
    [Google Scholar]
  13. Chillal A.S. Bhawale R.T. Kshirsagar U.A. Regioselective C(sp 2 )–H halogenation of pyrazolo[1,5- a ]pyrimidines facilitated by hypervalent iodine( iii ) under aqueous and ambient conditions. RSC Advances 2024 14 19 13095 13099 10.1039/D4RA02090A 38655480
    [Google Scholar]
  14. Chillal A.S. Bhawale R.T. Kshirsagar U.A. Oxone® Mediated Regioselective C(sp 2 )−H Selenylation and Thiocyanation of Pyrazolo[1,5‐ a ]pyrimidines at Room Temperature. ChemistrySelect 2024 9 1 e202304815 10.1002/slct.202304815
    [Google Scholar]
  15. Tiwari G. Mishra V.K. Kumari P. Khanna A. Sharma S. Sagar R. Synthesis of triazole bridged N -glycosides of pyrazolo[1,5- a ]pyrimidinones as anticancer agents and their in silico docking studies. RSC Advances 2024 14 2 1304 1315 10.1039/D3RA06993A 38174229
    [Google Scholar]
  16. Ruzi Z. Bozorov K. Nie L. Zhao J. Aisa H.A. Novel pyrazolo[3,4-d]pyrimidines as potential anticancer agents: Synthesis, VEGFR-2 inhibition, and mechanisms of action. Biomed. Pharmacother. 2022 156 113948 10.1016/j.biopha.2022.113948 36411633
    [Google Scholar]
  17. Zaki W.A. El-Sayed S.M. Alswah M. El-Morsy A. Bayoumi A.H. Mayhoub A.S. Moustafa W.H. Awaji A.A. Roh E.J. Hassan A.H.E. Mahmoud K. Design, Synthesis, In Vitro, and In Silico Studies of New N5-Substituted-pyrazolo[3,4-d]pyrimidinone Derivatives as Anticancer CDK2 Inhibitors. Pharmaceuticals (Basel) 2023 16 11 1593 10.3390/ph16111593 38004458
    [Google Scholar]
  18. Mahnashi M.H. El-Senduny F.F. Alshahrani M.A. Abou-Salim M.A. Design, synthesis, and biological evaluation of a novel VEGFR-2 inhibitor based on a 1, 2, 5-oxadiazole-2-oxide scaffold with MAPK signaling pathway inhibition. Pharmaceuticals (Basel) 2022 15 2 246 10.3390/ph15020246 35215358
    [Google Scholar]
  19. Gaber A.A. Abo Elmaaty A. Sharaky M. Mosa A.A. Yahya Abdullah Alzahrani A. Shaaban S. Eldehna W.M. Al-Karmalawy A.A. Multi-target rational design and synthesis of novel diphenyl-tethered pyrazolopyrimidines targeting EGFR and topoisomerase II with potential DNA intercalation and apoptosis induction. Bioorg. Chem. 2024 145 107223 10.1016/j.bioorg.2024.107223 38387399
    [Google Scholar]
  20. Abdelgawad M.A. Elkanzi N.A.A. Nayl A.A. Musa A. Alotaibi N.H. Arafa W.A.A. Gomha S.M. Bakr R.B. Targeting tumor cells with pyrazolo[3,4-d]pyrimidine scaffold: A literature review on synthetic approaches, structure activity relationship, structural and target-based mechanisms. Arab. J. Chem. 2022 15 5 103781 10.1016/j.arabjc.2022.103781
    [Google Scholar]
  21. Baillache DJ Unciti-Broceta A . Recent developments in anticancer kinase inhibitors based on the pyrazolo [3, 4-d] pyrimidine scaffold. RSC medicinal Chem 2020 11 10 1112
    [Google Scholar]
  22. Alhamaky S.M. Khalil N.A. Bass A.K.A. Osama N. Hassan M.S.A. Design, synthesis, docking studies, and investigation of dual EGFR/VEGFR‐2 inhibitory potentials of new pyrazole and pyrazolopyridine derivatives. Drug Dev. Res. 2025 86 1 e70056 10.1002/ddr.70056 39907164
    [Google Scholar]
  23. Abdulrahman F.G. Sabour R. El-Gilil S.M.A. Mehany A.B.M. Taha E.A. Design, synthesis, biological evaluation and molecular docking study of new pyrazolo[1,5-a]pyrimidines as PIM kinase inhibitors and apoptosis inducers. J. Mol. Struct. 2024 1295 136811 10.1016/j.molstruc.2023.136811
    [Google Scholar]
  24. Dai X. Wang L.J. Wu J. Shi Y.X. Li G.P. Yang X.Q. Src kinase inhibitor PP2 regulates the biological characteristics of A549 cells via the PI3K/Akt signaling pathway. Oncol. Lett. 2018 16 4 5059 5065 10.3892/ol.2018.9282 30250573
    [Google Scholar]
  25. Elbakry O.M. Harras M.F. Elsebaei M.M. Mehany A. Elsehrawi H. Development of pyrazolo [1, 5-a] pyrimidine derivatives: Synthesis, anticancer activity and docking study. Azhar International Journal of Pharmaceutical and Medical Sciences. 2024 4 1 76 90
    [Google Scholar]
  26. Fraser C. Dawson J.C. Dowling R. Houston D.R. Weiss J.T. Munro A.F. Muir M. Harrington L. Webster S.P. Frame M.C. Brunton V.G. Patton E.E. Carragher N.O. Unciti-Broceta A. Rapid discovery and structure–activity relationships of pyrazolopyrimidines that potently suppress breast cancer cell growth via SRC kinase inhibition with exceptional selectivity over ABL kinase. J. Med. Chem. 2016 59 10 4697 4710 10.1021/acs.jmedchem.6b00065 27115835
    [Google Scholar]
  27. Hanke J.H. Gardner J.P. Dow R.L. Changelian P.S. Brissette W.H. Weringer E.J. Pollok B.A. Connelly P.A. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J. Biol. Chem. 1996 271 2 695 701 10.1074/jbc.271.2.695 8557675
    [Google Scholar]
  28. Shah O.J. Kimball S.R. Jefferson L.S. The Src-family tyrosine kinase inhibitor PP1 interferes with the activation of ribosomal protein S6 kinases. Biochem. J. 2002 366 1 57 62 10.1042/bj20020198 12014987
    [Google Scholar]
  29. Tiwari G. Khanna A. Tyagi R. Mishra V.K. Narayana C. Sagar R. Copper-catalyzed synthesis of pyrazolo[1,5-a]pyrimidine based triazole-linked glycohybrids: mechanistic insights and bio-applications. Sci. Rep. 2024 14 1 529 10.1038/s41598‑023‑50202‑4 38177184
    [Google Scholar]
  30. Hassaballah A.I. AboulMagd A.M. Hemdan M.M. Hekal M.H. El-Sayed A.A. Farag P.S. New pyrazolo[3,4- d ]pyrimidine derivatives as EGFR-TK inhibitors: design, green synthesis, potential anti-proliferative activity and P-glycoprotein inhibition. RSC Advances 2024 14 3 1995 2015 10.1039/D3RA05401B 38196910
    [Google Scholar]
  31. El-Gamal M.I. Zaraei S.O. Madkour M.M. Anbar H.S. Evaluation of substituted pyrazole-based kinase inhibitors in one decade (2011–2020): Current status and future prospects. Molecules 2022 27 1 330 10.3390/molecules27010330 35011562
    [Google Scholar]
  32. Hassan R.A. Kadry H.H. Sayed R.G. Abdou A.M. Refaey R.H. Design, synthesis, and anticancer evaluation of new pyrazolo[3,4-d]pyrimidine-based derivatives: CDK2 inhibition, apoptosis-inducing activity, molecular modelling studies. Bioorg. Med. Chem. 2025 128 118286 10.1016/j.bmc.2025.118286 40554253
    [Google Scholar]
  33. Elgiushy H.R. Soliman M.E. El-Khouly M.E. Abouzid K.A.M. Hammad S.F. Discovery of pyrazolo[1,5-a]pyrimidines: Synthesis, in silico insights, and anticancer activity via novel CDK2/Tubulin dual inhibition approach. Bioorg. Chem. 2025 164 108792 10.1016/j.bioorg.2025.108792 40815993
    [Google Scholar]
  34. Gaber A.A. Bayoumi A.H. El-morsy A.M. Sherbiny F.F. Mehany A.B.M. Eissa I.H. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFRWT and EGFRT790M inhibitors and apoptosis inducers. Bioorg. Chem. 2018 80 375 395 10.1016/j.bioorg.2018.06.017 29986185
    [Google Scholar]
  35. Dash A. Vaddamanu G. Hawsawi M.B. Alluhaibi M.S. Gurijala P.K. Mulakayala N. Design, synthesis, and high-throughput in vitro anti-cancer evaluation of novel 4-aminopyrazolo[3,4- d ]pyrimidine derivatives: potential anti-cancer candidates against UO-31 renal cancer cells. RSC Advances 2024 14 42 30938 30953 10.1039/D4RA05136J 39346525
    [Google Scholar]
  36. Zhang Y. Liu Y. Zhou Y. Zhang Q. Han T. Tang C. Fan W. Pyrazolo[1,5-a]pyrimidine based Trk inhibitors: Design, synthesis, biological activity evaluation. Bioorg. Med. Chem. Lett. 2021 31 127712 10.1016/j.bmcl.2020.127712 33246108
    [Google Scholar]
  37. Chen S. Yang Y. Yuan Y. Bo Liu Targeting PIM kinases in cancer therapy: An update on pharmacological small-molecule inhibitors. Eur. J. Med. Chem. 2024 264 116016 10.1016/j.ejmech.2023.116016 38071792
    [Google Scholar]
  38. Khalifa H. ElHady A.K. Liu T. Elgaher W.A.M. Filhol-Cochet O. Cochet C. Abadi A.H. Hamed M.M. Abdel-Halim M. Engel M. Discovery of a novel, selective CK2 inhibitor class with an unusual basic scaffold. Eur. J. Med. Chem. 2025 282 117048 10.1016/j.ejmech.2024.117048 39566243
    [Google Scholar]
  39. Halder P. Rai A. Talukdar V. Das P. Lakkaniga N.R. Pyrazolopyridine-based kinase inhibitors for anti-cancer targeted therapy. RSC Medicinal Chemistry 2024 15 5 1452 1470 10.1039/D4MD00003J 38784451
    [Google Scholar]
  40. Al-Qadhi M.A. Yahya T.A.A. El-Nassan H.B. Recent advances in the discovery of CK2 inhibitors. ACS Omega 2024 9 19 20702 20719 10.1021/acsomega.3c10478 38764653
    [Google Scholar]
  41. Gu Y.Q. Ma M.X. Yang Q.Y. Yang K. Li H.Q. Hu M.Q. Liang H. Chen Z.F. In vitro and in vivo anticancer activity of novel Rh(III) and Pd(II) complexes with pyrazolopyrimidine derivatives. Bioorg. Chem. 2023 141 106838 10.1016/j.bioorg.2023.106838 37717414
    [Google Scholar]
  42. Sivaiah G. Raveesha R. Prasad S.B.B. Kumar K.Y. Raghu M.S. Alharethy F. Prashanth M. Jeon B.H. Synthesis, anticancer activity and molecular docking of new pyrazolo[1,5-a]pyrimidine derivatives as EGFR/HER2 dual kinase inhibitors. J. Mol. Struct. 2023 1289 135877 10.1016/j.molstruc.2023.135877
    [Google Scholar]
  43. Gaber A.A. Sharaky M. Elmaaty A.A. Hammouda M.M. Mourad A.A.E. Elkhawaga S.Y. Mokhtar M.M. Abouzied A.S. Mourad M.A.E. Al-Karmalawy A.A. Design and synthesis of novel pyrazolopyrimidine candidates as promising EGFR-T790M inhibitors and apoptosis inducers. Future Med. Chem. 2023 15 19 1773 1790 10.4155/fmc‑2023‑0156 37882053
    [Google Scholar]
  44. Tatton L. Morley G.M. Chopra R. Khwaja A. The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases. J. Biol. Chem. 2003 278 7 4847 4853 10.1074/jbc.M209321200 12475982
    [Google Scholar]
  45. Karni R. Mizrachi S. Reiss-Sklan E. Gazit A. Livnah O. Levitzki A. The pp60 c‐Src inhibitor PP1 is non‐competitive against ATP. FEBS Lett. 2003 537 1-3 47 52 10.1016/S0014‑5793(03)00069‑3 12606029
    [Google Scholar]
  46. Salazar E.P. Rozengurt E. Src family kinases are required for integrin-mediated but not for G protein-coupled receptor stimulation of focal adhesion kinase autophosphorylation at Tyr-397. J. Biol. Chem. 2001 276 21 17788 17795 10.1074/jbc.M100984200 11279163
    [Google Scholar]
  47. Hossan A. Alrefaei A.F. Katouah H.A. Bayazeed A. Asghar B.H. Shaaban F. El-Metwaly N.M. Synthesis, anticancer activity, and molecular docking of new pyrazolo[1,5-a]pyrimidine derivatives. J. Saudi Chem. Soc. 2023 27 2 101599 10.1016/j.jscs.2023.101599
    [Google Scholar]
  48. Hossan A. Aljohani M. Alrefaei A.F. Althumayri K. Bayazeed A. Saad F.A. Abumelha H.M. El-Metwaly N.M. Synthesis of functionalized aminopyrazole and pyrazolopyrimidine derivatives: Molecular modeling and docking as anticancer agents. Arab. J. Chem. 2023 16 4 104645 10.1016/j.arabjc.2023.104645
    [Google Scholar]
  49. Singh A.K. Sonawane P. Kumar A. Singh H. Naumovich V. Pathak P. Grishina M. Khalilullah H. Jaremko M. Emwas A.H. Verma A. Kumar P. Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022. ACS Omega 2023 8 31 27819 27844 10.1021/acsomega.3c00332 37576670
    [Google Scholar]
  50. Yevale D.B. Teraiya N. Lalwani T.D. Ameta R.K. Sangani C.B. A novel class of pyrazole analogues as aurora kinase A inhibitor: design, synthesis, and anticancer evaluation. Bioorg. Chem. 2023 141 106901 10.1016/j.bioorg.2023.106901 37797455
    [Google Scholar]
  51. Azher O.A. Hossan A. Pashameah R.A. Alsoliemy A. Alharbi A. Habeebullah T.M. El-Metwaly N.M. Synthesis, anticancer evaluation, and molecular modeling study of new 2-(phenylamino)pyrazolo[1,5-a]pyrimidine analogues. Arab. J. Chem. 2023 16 1 104437 10.1016/j.arabjc.2022.104437
    [Google Scholar]
  52. Farghaly T.A. Gaber Abdulwahab H. Medrasi H.Y. Al-sheikh M.A. Katowah D.F. Alsaedi A.M.R. Novel 6,7,8-trihydrobenzo[6′,7′]cyclohepta[2′,1′-e]pyrazolo[2,3-a]pyrimidine derivatives as Topo IIα inhibitors with potential cytotoxic activity. Bioorg. Chem. 2022 128 106043 10.1016/j.bioorg.2022.106043 36058118
    [Google Scholar]
  53. Younes A. Shawer T. El-Sehrawi H. Design, synthesis and antiproliferative evaluation of novel Pyrazolo-pyrimidine derivatives with expected Cyclin-dependent kinase 2 inhibitory effect. Azhar Int. J. Pharma. Med. Sci. 2022 0 0 0 10.21608/aijpms.2022.77353.1075
    [Google Scholar]
  54. Zhang M. Wei W. Peng C. Ma X. He X. Zhang H. Zhou M. Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy. Bioorg. Med. Chem. Lett. 2021 49 128286 10.1016/j.bmcl.2021.128286 34314844
    [Google Scholar]
  55. Othman E.M. Bekhit A.A. Anany M.A. Dandekar T. Ragab H.M. Wahid A. Design, synthesis, and anticancer screening for repurposed pyrazolo [3, 4-d] pyrimidine derivatives on four mammalian cancer cell lines. Molecules 2021 26 10 2961 10.3390/molecules26102961 34065773
    [Google Scholar]
  56. Soliman N.N. Tag Y.M. Bayoumy N.M. Synthesis and molecular docking of some new 3,5‐bis‐(diazipine, pyrazolopyrimidine, pyrimidine, and pyrazole) pyridine derivatives and their in vitro and in vivo biological evaluation as potential antitumor agents. J. Heterocycl. Chem. 2021 58 5 1141 1153 10.1002/jhet.4244
    [Google Scholar]
  57. Fathy U. Abu-Hashem A.A. Gouhar R.S. Awad H.M. Elgamal A.M. Synthesis, structural characterization of some pyrazolo [1, 5-a] pyrimidine and imidazo [1, 2-b] pyrazole derivatives as anticancer activity. Rasayan J. Chem. 2021 14 741 750 10.31788/RJC.2021.1426137
    [Google Scholar]
  58. Wang Y. Liu Y. Zhang Y. Zhang Z. Xu L. Wang J. Yang Y. Hu B. Yao Y. Wei M. Wang J. Tang B. Zhang K. Liu S. Yang G. Design, synthesis and evaluation of a pyrazolo[3,4-d]pyrimidine derivative as a novel and potent TGFβ1R1 inhibitor. Eur. J. Med. Chem. 2024 271 116395 10.1016/j.ejmech.2024.116395 38626523
    [Google Scholar]
  59. Hamed O.A. Abou-Elmagd El-Sayed N. Mahmoud W.R. F Elmasry G. Molecular docking approach for the design and synthesis of new pyrazolopyrimidine analogs of roscovitine as potential CDK2 inhibitors endowed with pronounced anticancer activity. Bioorg. Chem. 2024 147 107413 10.1016/j.bioorg.2024.107413 38696844
    [Google Scholar]
  60. Adel D. El-Adl K. Nasr T. Sakr T.M. Zaghary W. Pyrazolo[3,4-d]pyrimidine derivatives as EGFRT790M and VEGFR-2 dual TK inhibitors: Design, synthesis, molecular docking, ADMET profile and anticancer evaluations. J. Mol. Struct. 2023 1291 136047 10.1016/j.molstruc.2023.136047
    [Google Scholar]
  61. Jovanović Stojanov S. Kostić A. Ljujić M. Lupšić E. Schenone S. Pešić M. Dinić J. Autophagy inhibition enhances anti-glioblastoma effects of pyrazolo [3, 4-d] pyrimidine tyrosine kinase inhibitors. Life (Basel) 2022 12 10 1503 10.3390/life12101503 36294938
    [Google Scholar]
  62. Greco C. Taresco V. Pearce A.K. Vasey C.E. Smith S. Rahman R. Alexander C. Cavanagh R.J. Musumeci F. Schenone S. Development of pyrazolo [3, 4-d] pyrimidine kinase inhibitors as potential clinical candidates for glioblastoma multiforme. ACS Med. Chem. Lett. 2020 11 5 657 663 10.1021/acsmedchemlett.9b00530 32435367
    [Google Scholar]
  63. Wu X. Xu Y. Liang Q. Yang X. Huang J. Wang J. Zhang H. Shi J. Recent advances in dual PI3K/mTOR inhibitors for tumour treatment. Front. Pharmacol. 2022 13 875372 10.3389/fphar.2022.875372 35614940
    [Google Scholar]
  64. Abdelhamed A.M. Hassan R.A. Kadry H.H. Helwa A.A. Novel pyrazolo[3,4- d ]pyrimidine derivatives: design, synthesis, anticancer evaluation, VEGFR-2 inhibition, and antiangiogenic activity. RSC Medicinal Chemistry 2023 14 12 2640 2657 10.1039/D3MD00476G 38107182
    [Google Scholar]
  65. Mao B. Zhang Q. Ma L. Zhao D.S. Zhao P. Yan P. Overview of research into mTOR inhibitors. Molecules 2022 27 16 5295 10.3390/molecules27165295 36014530
    [Google Scholar]
  66. Ali E.S. Mitra K. Akter S. Ramproshad S. Mondal B. Khan I.N. Islam M.T. Sharifi-Rad J. Calina D. Cho W.C. Recent advances and limitations of mTOR inhibitors in the treatment of cancer. Cancer Cell Int. 2022 22 1 284 10.1186/s12935‑022‑02706‑8 36109789
    [Google Scholar]
  67. Jiang T. Wang G. Liu Y. Feng L. Wang M. Liu J. Chen Y. Ouyang L. Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers. Acta Pharm. Sin. B 2021 11 2 355 372 10.1016/j.apsb.2020.05.004 33643817
    [Google Scholar]
  68. Carlson J.J. Italiano A. Brose M.S. Federman N. Lassen U. Kummar S. Sullivan S.D. Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer. Am. J. Manag. Care 2022 28 2 Suppl. S26 S32 35201681
    [Google Scholar]
  69. Hammouda M.M. Gaffer H.E. Elattar K.M. Insights into the medicinal chemistry of heterocycles integrated with a pyrazolo[1,5- a ]pyrimidine scaffold. RSC Medicinal Chemistry 2022 13 10 1150 1196 10.1039/D2MD00192F 36325400
    [Google Scholar]
  70. Hanan E.J. van Abbema A. Barrett K. Blair W.S. Blaney J. Chang C. Eigenbrot C. Flynn S. Gibbons P. Hurley C.A. Kenny J.R. Kulagowski J. Lee L. Magnuson S.R. Morris C. Murray J. Pastor R.M. Rawson T. Siu M. Ultsch M. Zhou A. Sampath D. Lyssikatos J.P. Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors. J. Med. Chem. 2012 55 22 10090 10107 10.1021/jm3012239 23061660
    [Google Scholar]
  71. Wang Z. Machine learning-based prediction of ADMET properties for kinase inhibitors. J. Chem. Inf. Model. 2024 64 2 1213 1225 10.1021/acs.jcim.3c01964 38302422
    [Google Scholar]
  72. Patel N. Sustainable mechanochemical synthesis of heterocycles: pyrazolopyrimidines case study. Green Chem. 2024 26 4 2156 2167
    [Google Scholar]
  73. Yao D. Jiang J. Zhang H. Huang Y. Huang J. Wang J. Design, synthesis and biological evaluation of dual mTOR/HDAC6 inhibitors in MDA-MB-231 cells. Bioorg. Med. Chem. Lett. 2021 47 128204 10.1016/j.bmcl.2021.128204 34139324
    [Google Scholar]
  74. Chi Y.H. Yeh T.K. Ke Y.Y. Lin W.H. Tsai C.H. Wang W.P. Chen Y.T. Su Y.C. Wang P.C. Chen Y.F. Wu Z.W. Yeh J.Y. Hung M.C. Wu M.H. Wang J.Y. Chen C.P. Song J.S. Shih C. Chen C.T. Chang C.P. Discovery and synthesis of a pyrimidine-based aurora kinase inhibitor to reduce levels of MYC oncoproteins. J. Med. Chem. 2021 64 11 7312 7330 10.1021/acs.jmedchem.0c01806 34009981
    [Google Scholar]
  75. Choy L. Norris S. Wu X. Kolumam G. Firestone A. Settleman J. Stokoe D. Inhibition of Aurora Kinase Induces Endogenous Retronlms to Induce a Type I/III IFN Response via RIG-I. Cancer Research Communications 2024 4 2 540 555 10.1158/2767‑9764.CRC‑23‑0432 38358346
    [Google Scholar]
  76. Jing X.L. Chen S.W. Aurora kinase inhibitors: a patent review (2014-2020). Expert Opin. Ther. Pat. 2021 31 7 625 643 10.1080/13543776.2021.1890027 33573401
    [Google Scholar]
  77. Elkotamy M.S. Elkelesh I.A. Giovannuzzi S. Ismail R.S.M. El-Refaie W.M. Almehizia A.A. Naglah A.M. Nocentini A. Supuran C.T. Fares M. Ghabbour H.A. Salem R. Eldehna W.M. Abdel-Aziz H.A. Rationally designed Pyrazolo[1,5-a]pyrimidines as dual inhibitors of CA IX/XII and CDK6: A novel approach for NSCLC treatment. Eur. J. Med. Chem. 2025 293 117752 10.1016/j.ejmech.2025.117752 40373635
    [Google Scholar]
  78. K M.S. Rathi E. Udupa K.S. Prasada K S. Pai K.S.R. Kini S.G. Design of PI3K-mTOR Dual Inhibitors for Ovarian Cancer: Are we on the Right Track? Curr. Med. Chem. 2025 32 6 1121 1143 10.2174/0109298673293028240326051835 38584538
    [Google Scholar]
  79. Aziz M.A. Serya R.A.T. Lasheen D.S. Abdel-Aziz A.K. Esmat A. Mansour A.M. Singab A.N.B. Abouzid K.A.M. Discovery of potent VEGFR-2 inhibitors based on furopyrimidine and thienopyrimidine scaffolds as cancer targeting agents. Sci. Rep. 2016 6 1 24460 10.1038/srep24460 27080011
    [Google Scholar]
  80. Singh S. Barik D. Lawrie K. Mohapatra I. Prasad S. Naqvi A.R. Singh A. Singh G. Unveiling novel avenues in mTOR-targeted therapeutics: advancements in glioblastoma treatment. Int. J. Mol. Sci. 2023 24 19 14960 10.3390/ijms241914960 37834408
    [Google Scholar]
  81. Lei Z.N. Tian Q. Teng Q.X. Wurpel J.N.D. Zeng L. Pan Y. Chen Z.S. Understanding and targeting resistance mechanisms in cancer. MedComm 2023 4 3 e265 10.1002/mco2.265 37229486
    [Google Scholar]
  82. Roszkowska M. Multilevel mechanisms of cancer drug resistance. Int. J. Mol. Sci. 2024 25 22 12402 10.3390/ijms252212402 39596466
    [Google Scholar]
  83. Koirala M. DiPaola M. Overcoming cancer resistance: Strategies and modalities for effective treatment. Biomedicines 2024 12 8 1801 10.3390/biomedicines12081801 39200265
    [Google Scholar]
  84. Smerdi D. Moutafi M. Kotsantis I. Stavrinou L.C. Psyrri A. Overcoming resistance to temozolomide in glioblastoma: a scoping review of preclinical and clinical data. Life (Basel) 2024 14 6 673 10.3390/life14060673 38929657
    [Google Scholar]
  85. Tumu S. Rao A.S.S. Ega J.K. Synthesis of fully substituted 1,2,3-Triazoles via Organocatalytic [3+2] Cycloaddition: Incorporation of Pyrazole and Imidazole Scaffolds as Potent EGFR-Targeted Anticancer Agents. Russ. J. Bioorganic Chem. 2025 51 4 1700 1714 10.1134/S1068162024606633
    [Google Scholar]
  86. Singh H.K. Kamal A. Maury S.K. Kushwaha A.K. Srivastava V. Singh S. A green synthesis of pyrimido[4,5- b ]quinolines and pyrido[2,3- d ]pyrimidines via a mechanochemical approach. Org. Biomol. Chem. 2023 21 23 4854 4862 10.1039/D3OB00626C 37249156
    [Google Scholar]
  87. Shaban R.M. Samir N. Nissan Y.M. Abouzid K.A.M. Design, synthesis, and biological evaluation with molecular dynamics study of novel pyrazolo[3,4- d ]pyrimidine derivatives as anti-cancer agents. RSC Advances 2023 13 25 17074 17096 10.1039/D3RA00446E 37293475
    [Google Scholar]
  88. Zhu S.K. Wu Q. Liu G.X. Geng A.Q. Wang P.A. Recent advances in focal adhesion kinase (FAK)-targeting antitumor agents. RSC Advances 2025 15 26 20957 20984 10.1039/D5RA01880C 40546697
    [Google Scholar]
  89. Wang X. Li N. Liu Y.H. Wu J. Liu Q.G. Niu J.B. Xu Y. Huang C.Z. Zhang S.Y. Song J. Targeting focal adhesion kinase (FAK) in cancer therapy: A recent update on inhibitors and PROTAC degraders. Eur. J. Med. Chem. 2024 276 116678 10.1016/j.ejmech.2024.116678 39029337
    [Google Scholar]
  90. Hu H.H. Wang S.Q. Shang H.L. Lv H.F. Chen B.B. Gao S.G. Chen X.B. Roles and inhibitors of FAK in cancer: current advances and future directions. Front. Pharmacol. 2024 15 1274209 10.3389/fphar.2024.1274209 38410129
    [Google Scholar]
  91. Lu Y. Sun H. Progress in the development of small molecular inhibitors of focal adhesion kinase (FAK). J. Med. Chem. 2020 63 23 14382 14403 10.1021/acs.jmedchem.0c01248 33058670
    [Google Scholar]
  92. Venice Green Chemistry School Proceedings of the 16th Green Chemistry Postgraduate Summer School Venice, Italy, Jun 30-Jul 5, 2024.
    [Google Scholar]
  93. Chhikara B.S. Ashraf S. Mozaffari S. St Jeans N. Mandal D. Tiwari R.K. Ul-Haq Z. Parang K. Phenylpyrazalopyrimidines as tyrosine kinase inhibitors: synthesis, antiproliferative activity, and molecular simulations. Molecules 2020 25 9 2135 10.3390/molecules25092135 32370213
    [Google Scholar]
  94. Cinar-Asa S. Coskun D. Akgun O. Akgun H. Fatih Coskun M. Ari F. Design, synthesis and anticancer activity of new Benzofuran‐Chalcone hybrids and their water soluble sodium salts. ChemistrySelect 2023 8 9 e202204402 10.1002/slct.202204402
    [Google Scholar]
  95. Attia M.H. Lasheen D.S. Samir N. Taher A.T. Abdel-Aziz H.A. Abou El Ella D.A. Design, synthesis and molecular modeling of Pyrazolo [1, 5-a] pyrimidine derivatives as dual inhibitors of CDK2 and TRKA kinases with Antiproliferative activity. Pharmaceuticals 2024 17 12 1667 10.3390/ph17121667 39770509
    [Google Scholar]
  96. Xie li Y.U. Houxing Q Pyrazolo[3,4-d]pyrimidin-3-one derivatives as Wee-1 inhibitors. WO patent 2022171128A1 2022
  97. Pyrazolo[3,4-d]pyrimidine derivatives for treatment of HER2-positive tumors. EP 3845231 A1 2021
  98. Crystal forms of a pyrazolo[3,4-d]pyrimidine antitumor agent. EP Patent 3845537A1 2021
  99. Pyrazolopyrimidine derivatives as HPK1 inhibitors for immuno-oncology. US Patent 11014929 B2 2021
  100. Pyrazolopyrimidine derivatives as ATR inhibitors. WO patent 2023138343 2023
  101. Pyrazolopyrimidine derivatives as TET2 inhibitors. WO Patent 2023214325 2023
  102. Brubaker J.D. Kim J.L. Wilson K.J. Wilson D. DiPietro L.V. Pyrazolo[3,4-d]pyrimidine derivatives as RET kinase inhibitors for targeted cancer therapy. US patent 11273160 B2 2022
  103. El-Desouky S.I. Nafie M.S. Haffez H. Moustafa M.A.A. Ali A.R. Scaffold-hopping strategy for pyrazolo[3,4-d]pyrimidines: In vitro and in silico studies of dual c-Met/STAT3 inhibition for enhanced antitumor activity. Bioorg. Chem. 2025 164 108821 10.1016/j.bioorg.2025.108821 40782411
    [Google Scholar]
  104. Alamshany Z.M. Algamdi E.M. Othman I.M.M. Anwar M.M. Nossier E.S. New pyrazolopyridine and pyrazolothiazole-based compounds as anti-proliferative agents targeting c-Met kinase inhibition: design, synthesis, biological evaluation, and computational studies. RSC Advances 2023 13 19 12889 12905 10.1039/D3RA01931D 37114032
    [Google Scholar]
  105. Jin F. Lin Y. Yuan W. Wu S. Yang M. Ding S. Liu J. Chen Y. Recent advances in c-Met-based dual inhibitors in the treatment of cancers. Eur. J. Med. Chem. 2024 272 116477 10.1016/j.ejmech.2024.116477 38733884
    [Google Scholar]
/content/journals/mrmc/10.2174/0113895575417710251128043828
Loading
A Comprehensive Review of Designing and Synthetic Aspects of Pyrazolopyrimidine Derivatives as Anticancer Agents
Bentham Science Publishers ; https://doi.org/10.2174/0113895575417710251128043828
/content/journals/mrmc/10.2174/0113895575417710251128043828
/content/journals/mrmc/10.2174/0113895575417710251128043828
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: cancer cells ; molecular docking ; kinase inhibitor ; anticancer agents ; synthesis ; Pyrazolopyrimidine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test